MP45: Prostate Cancer: Markers

Poster Session Moderator(s)

• 

  Daniel Lin, MD

  University of Washington
• 

  Ketan Badani, MD

  Icahn School of Medicine at Mount Sinai Hospital
• 

  Jose Luis Alvarez Ossorio Fernandez, MD, PHD

  Puerta del Mar University Hospital. Cádiz Spain

Presentations:

• 1:00 PM – 2:15 PM

  MP45-01: A new serum biomarker to predict the risk of prostate cancer at biopsy: Pentraxin-3
  

  Poster Presenter: Gian Maria Busetto
• 1:00 PM – 2:15 PM

  MP45-02: A prospective study of the prostate health index density and multiparametric magnetic resonance imaging in diagnosing clinically significant prostate cancer
  

  Poster Presenter: Gang Song
• 1:00 PM – 2:15 PM

  MP45-03: Urinary exosome microRNA signatures as a noninvasive prognostic biomarker for prostate cancer
  

  Poster Presenter: Hyeok Jae Kwon, MD – Seoul ST. Mary’S Hospita
• 1:00 PM – 2:15 PM

  MP45-04: SelectMDx Urine Test Diagnose Men with High-Grade Prostate Cancer
  

  Poster Presenter: E. David Crawford, MD
• 1:00 PM – 2:15 PM

  MP45-05: MicroRNA 185-5p is a novel biomarker associated with high-risk pathology at radical prostatectomy in patients with low-risk disease at diagnosis
  

  Poster Presenter: Kevin Shee, MD, PHD – UCSF Urology
• 1:00 PM – 2:15 PM

  MP45-06: Clinical significance of &[alpha]2,3-sialylated prostate-specific antigen density and MRI for high-grade prostate cancer in biopsy-naïve men with elevated PSA level.
  

  Poster Presenter: Tohru Yoneyama, PhD – Department of Glycotechnology, Advanced Medical Re
• 1:00 PM – 2:15 PM

  MP45-07: Oncologic Outcomes of Total Length Gleason Pattern 4 on Biopsy in Men with Grade Group 2 Prostate Cancer
  

  Poster Presenter: Marlon L. Perera, MD – Austin Health
• 1:00 PM – 2:15 PM

  MP45-08: A Comparison of Biopsy Genomic Test to Predict Adverse Disease on Prostatectomy
  

  Poster Presenter: Alex Uhr, MD
• 1:00 PM – 2:15 PM

  MP45-09: Discriminative Significance of Prostate Biopsy Decipher Score to Predict Adverse Pathology and Pathological Discordance at Radical Prostatectomy
  

  Poster Presenter: Ghazal Khajir, MD – Yale School of Medicine
• 1:00 PM – 2:15 PM

  MP45-10: Does Perioperative Testosterone predict Post-Prostatectomy Genomic Risk Score?
  

  Poster Presenter: Mohammed Darwish Shahait, MD – King Hussein Cancer Center
• 1:00 PM – 2:15 PM

  MP45-11: Metabolomics of Black-White differences in risk of prostate cancer biochemical recurrence
  

  Poster Presenter: Bruce J. Trock, PhD
• 1:00 PM – 2:15 PM

  MP45-12: PTEN Loss and Diffusive Ki67 Predict Biochemical Recurrence of Localized Prostate Cancer After Radical Prostatectomy: A Validation Cohort Study
  

  Poster Presenter: Che Hsueh Yang, MD – Tungs' Taichung Metroharbor Hospital
• 1:00 PM – 2:15 PM

  MP45-13: Association Between Polymorphisms of Homologous Recombination RAD51B and Disease Recurrence in a Prospective Cohort of Prostate Cancer Patients Undergoing Radical Prostatectomy
  

  Poster Presenter: Vito Cucchiara
• 1:00 PM – 2:15 PM

  MP45-14: The spatial landscape of clonal somatic mutations in benign and malignant prostate epithelia
  

  Poster Presenter: Alastair Lamb, MD, FRCS – Nuffield Department of Surgical Sciences
• 1:00 PM – 2:15 PM

  MP45-15: PTEN Loss and Diffusive Ki67 Are Related to Castration-Resistant Prostate Cancer: A Validation Cohort Study
  

  Poster Presenter: Che Hsueh Yang, MD – Tungs' Taichung Metroharbor Hospital
• 1:00 PM – 2:15 PM

  MP45-16: CRISRP screens reveal determinants of PARP inhibitor response in prostate cancer
  

  Poster Presenter: Takuya Tsujino
• 1:00 PM – 2:15 PM

  MP45-17: Correlation between CTC counts and radiomic metrics from multiple osseous metastatic lesions in metastatic prostate cancer
  

  Poster Presenter: Vinay Duddalwar, MD, MBBS – University of Southern California
• 1:00 PM – 2:15 PM

  MP45-18: Identification of DNA Damage Repair-Associated Prognostic Biomarkers for Prostate Cancer Using Transcriptomic Data Analysis
  

  Poster Presenter: Shu-Pin Huang, MD, PHD – Kaohsiung Medical University Hospital
• 1:00 PM – 2:15 PM

  MP45-19: Comparison of predictive markers of effectiveness of PARP inhibitors vs immunotherapy for treatment of clinically advanced prostate cancer (CAPC) based on TMPRSS2:ERG fusion status
  

  Poster Presenter: Aleksandar Popovic, BS
• 1:00 PM – 2:15 PM

  MP45-20: Variability in testosterone measurement between radioimmunoassay (RIA), chemiluminescence assay(CLIA) and liquid chromatography-tandem mass spectrometry(MS) among prostate cancer patients on androgen deprivation therapy (ADT).
  

  Poster Presenter: Raj Vikesh Tiwari, MD, FRCS – Sengkang General Hospital